Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WEDGE: an anticoagulant thrombin mutant produced by autoactivation.

Journal of thrombosis and haemostasis : JTH - 1 Jan 2015

Wood D C, Pelc L A, Pozzi N, Wallisch M, Verbout N G, Tucker E I, Gruber A, Di Cera E

Abstract excerpt

BACKGROUND: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. OBJECTIVES: Autoactivation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Blood Coagulation
Share to Injections, Intravenous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Partial Thromboplastin Time

Share to Protein Engineering

Share to Prothrombin

Share to Thrombin

Source

Open in PubMed Open full text

Identifiers

PMID: 25369995
DOI: 10.1111/jth.12774
PMCID: PMC4368433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WEDGE: an anticoagulant thrombin mutant produced by autoactivation.PMID 25369995Read ↗

Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR1 or protein C.Semantic proximity Read ↗

The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII.Semantic proximity Read ↗

Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase.Semantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

Engineering a membrane-independent human prothrombinase through parsimonious mutation of factor XaSemantic proximity Read ↗

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.Semantic proximity Read ↗

Engineering thrombin for selective specificity toward protein C and PAR1.Semantic proximity Read ↗

Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis.Semantic proximity Read ↗

S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.Semantic proximity Read ↗

Engineering a membrane-independent human prothrombinase through parsimonious mutation of factor Xa.Semantic proximity Read ↗

Murine thrombin lacks Na+ activation but retains high catalytic activity.Semantic proximity Read ↗

Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.